Moderate

Constrictive (obliterative) bronchiolitis

small-airway fibrosis · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Constrictive bronchiolitis is irreversible small-airway fibrosis causing fixed airflow obstruction, seen after lung/stem-cell transplant, connective-tissue disease, toxic inhalation and certain infections. It often progresses despite treatment; early recognition and cause-directed therapy are key.

Red flags

  • Rapid FEV1 decline
  • Hypoxaemia / respiratory failure
  • Post-transplant: features of chronic rejection
  • Recurrent infection superimposed on fixed obstruction

Assessment

Differential diagnosis

  • Asthma / COPD
  • Bronchiectasis
  • Hypersensitivity pneumonitis
  • Chronic lung allograft dysfunction (post-transplant)
  • Diffuse panbronchiolitis

Investigations

  • Spirometry (fixed obstructive pattern, often with air trapping)
  • Expiratory HRCT (mosaic attenuation, air trapping, bronchial wall thickening)
  • Lung volumes and DLCO
  • History of transplant, connective-tissue disease, inhalational exposure or infection
  • Lung biopsy in selected diagnostic uncertainty

Management

  • Suspect in progressive fixed airflow obstruction not explained by asthma/COPD
  • Document the obstructive physiology and air trapping on expiratory CT
  • Identify the underlying cause (allograft rejection, GVHD, connective-tissue disease, toxic inhalation)
  • In transplant/stem-cell recipients, evaluate for chronic allograft dysfunction / GVHD
  • Optimise bronchodilator therapy (limited benefit but worth a trial)
  • Treat the underlying cause and modify immunosuppression where relevant
  • Trial azithromycin for its anti-inflammatory/immunomodulatory effect
  • Provide supportive care, pulmonary rehabilitation and oxygen assessment
  • Monitor lung function trajectory for progression
  • Refer progressive disease for lung transplant / re-transplant assessment

Drugs & doses

Azithromycin 250-500 mg PO three times weekly (immunomodulatory)
Inhaled LABA-LAMA +/- ICS as a trial
Optimise/modify systemic immunosuppression for post-transplant/GVHD disease
Montelukast / inhaled corticosteroid as adjuncts in selected cases

Disposition

Specialist respiratory / transplant clinic; cause-directed therapy; transplant assessment for progressive disease.

Complications & pitfalls

  • Progressive irreversible airflow obstruction
  • Respiratory failure
  • Recurrent infection
  • Graft loss in transplant recipients

Exam pearls

  • It causes fixed obstruction with minimal bronchodilator reversibility, distinguishing it from asthma
  • Expiratory CT air trapping and mosaicism are key radiological clues
  • Azithromycin may stabilise post-transplant bronchiolitis obliterans syndrome
  • Toxic inhalational exposures (e.g. diacetyl, nitrogen oxides, sulfur mustard) are classic causes

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.